May 13, 2022
2 min watch
Save
VIDEO: Outlook Therapeutics updates intravitreal bevacizumab path toward commercialization
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress here, Terry Dagnon, chief operations officer for Outlook Therapeutics, discusses the latest update on ONS-5010 for the treatment of wet AMD.
ONS-5010 is a formulation of bevacizumab being developed for intravitreal injection for the treatment of wet age-related macular degeneration and other retinal diseases. Currently, bevacizumab for intravitreal injection must be compounded from IV bevacizumab.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Dagnon reports being chief operations officer for Outlook Therapeutics.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.